Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Part of paid clinical trials in La Jolla, California.

Sponsor
AIDS Malignancy Consortium
Study ID
NCT04949464
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Computed Tomography — PROCEDURE
    Undergo LDCT
  • Smoking Cessation Intervention — BEHAVIORAL
    Use Positively Smoke Free - Mobile

Study Details

This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.

Key Dates

Start date
Mar 22, 2023
Status verified
Jun 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Prevention (smoking cessation, nicotine replacement, LDCT)
    Patients use the smartphone application, Positively Smoke Free - Mobile, for 42 days. Patients also receive nicotine replacement therapy for 12 weeks. Within 60 days of study registration, patients undergo LDCT.

Primary Outcome Measure

Rate of adherence to Positively Smoke Free - Mobile (PSF-M) [ Time Frame: Up to 42 days ]

Central Contacts

Locations (11)

FacilityCityStateZIPSite coordinators
UC San Diego Moores Cancer CenterLa JollaCalifornia92093
Jayamalee De Silva, MD
[email protected]
858-822-5377
Erin Reid, MD (PRINCIPAL_INVESTIGATOR)
George Washington UniversityWashington D.C.District of Columbia20052
Lakeisha McCormick
[email protected]
202-994-0872
Maria Elena Ruiz, MD (PRINCIPAL_INVESTIGATOR)
Moffitt Cancer CenterTampaFlorida33612
Alisia Sowden
[email protected]
813-745-6541
Anna Coghill, MD (PRINCIPAL_INVESTIGATOR)
Washington University School of MedicineSt LouisMissouri63110
Lee Ratner, MD, PhD
[email protected]
314-362-8836
Lee Ratner, MD, PhD (PRINCIPAL_INVESTIGATOR)
Mount Sinai HospitalNew YorkNew York10029
Keith Sigel, MD
[email protected]
212-659-8551
Keith Sigel, MD (PRINCIPAL_INVESTIGATOR)
Weill Cornell Medicine - Cornell Clinical Trials UnitNew YorkNew York10010
Kinge-Ann Marcelin
[email protected]
212-746-5613
Grant Ellsworth, MD (PRINCIPAL_INVESTIGATOR)
Montefiore Medical CenterThe BronxNew York10461
Jill Salvi
[email protected]
857-399-5039
Balazs Halmos, MD (PRINCIPAL_INVESTIGATOR)
The Ohio State University James Cancer HospitalColumbusOhio43221
Gretchen A McNally, MD
[email protected]
6142933196
Gretchan A McNally, MD (PRINCIPAL_INVESTIGATOR)
Thomas Jefferson UniversityPhiladelphiaPennsylvania19107
Julie Barta, MD
[email protected]
215-955-5161
Julie Barta, MD (PRINCIPAL_INVESTIGATOR)
University of Texas M.D. Anderson Cancer CenterHoustonTexas77030
Edwin Ostrin, MD
[email protected]
713-792-7734
Edwin Ostrin, MD (PRINCIPAL_INVESTIGATOR)
Virginia Mason Medical CenterSeattleWashington98101
Eliza Moore
[email protected]
206-287-6274
David Aboulafia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in La Jolla, CA

By condition
HIV
By specialty
Infectious disease
By research site
UC San Diego Moores Cancer Center· La Jolla, CAGeorge Washington University· Washington D.C., DCMoffitt Cancer Center· Tampa, FLWashington University School of Medicine· St Louis, MOMount Sinai Hospital· New York, NYWeill Cornell Medicine - Cornell Clinical Trials Unit· New York, NY

Related Studies